# A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR

> **NCT05660447** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Wills Eye** · enrollment: 80 (estimated)

## Conditions studied

- Rhegmatogenous Retinal Detachment
- Proliferative Vitreoretinopathy

## Interventions

- **DRUG:** Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA]
- **DRUG:** Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud

## Key facts

- **NCT ID:** NCT05660447
- **Lead sponsor:** Wills Eye
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-02-06
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-01-31
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2024-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05660447

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05660447, "A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT05660447. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*